Nicolas N Nassar (N N Nassar)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Acute Lymphoblastic Leukemia

Tyrosine Kinase

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Nature communications

Cincinnati Children's Hospital Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Cincinnati Children's Hospital Medical Center Oct 15 2010

United States

Associate Professor :: Experimental Hematology & Cancer Biology

Publications

R C Nayak, K H Chang, A K Singh, Michael Kotliar, M Desai, A M Wellendorf, M Wunderlich, J Bartram, Benjamin E Mizukawa, Myriam Cuadrado, Phillip J Dexheimer, Artem Barski, Xosé R Bustelo, Nicolas N Nassar, Jose A Cancelas
Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nature communications 13 (1) (2022)
Shailaja Hegde, Anjelika Gasilina, Mark Wunderlich, Yuan Lin, Marcel Buchholzer, Oliver H F Krumbach, Mohammad Akbarzadeh, Mohammad Reza Ahmadian, William L Seibel, Yi Zheng, John P Perentesis, Benjamin E Mizukawa, Lisa Privette Vinnedge, José A Cancelas, Nicolas N Nassar
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia (2021)
Anjelika Gasilina, Gurdat Premnauth, Purujit Gurjar, Jacek Biesiada, Shailaja Hegde, David Milewski, Gang Ma, Tanya V Kalin, Edward Merino, Jarek Meller, William Seibel, José A Cancelas, Lisa M Privette Vinnedge, Nicolas N Nassar
IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. PloS one 15 (3) (2020)